Pulmonary Arterial Hypertension - Epidemiology Forecast - 2032

DelveInsight's 'Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast-2032' report delivers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Pulmonary Arterial Hypertension Disease Understanding

Pulmonary Arterial Hypertension is a rare, progressive disorder characterized by hypertension in the pulmonary arteries for no apparent reason. It was defined by the 6th World Symposium on Pulmonary Hypertension (WSPH) as a resting mean pulmonary artery pressure (mPAP) of 20 mm Hg or greater, a normal end-expiratory pulmonary artery wedge pressure (PAWP) less than or equal to 15 mm Hg, and a PVR of greater than or equal to 3 Wood units.

Pulmonary Arterial Hypertension, symptoms generally occur due to insufficient oxygen in the blood; signs and symptoms of Pulmonary Arterial Hypertension worsen with the progression of the disease. In most cases, the initial symptom is severe shortness of breath following exertion. Additional symptoms include excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes; Pulmonary Arterial Hypertension symptoms are usually due to insufficient oxygen in the blood. In most cases, the initial symptom is severe shortness of breath following exertion. Additional symptoms include excessive fatigue, weakness, chest pain, dizzy spells, and fainting episodes.

Pulmonary Arterial Hypertension is classified based on the cause of the underlying disease pathogenesis as Idiopathic Pulmonary Arterial Hypertension (IPAH), Heritable Pulmonary Arterial Hypertension (HPAH), and Pulmonary Arterial Hypertension associated with conditions (APAH) such as connective tissue disease (CTD)-Pulmonary Arterial Hypertension, HIV-Pulmonary Arterial Hypertension, congenital heart disease (CHD)-Pulmonary Arterial Hypertension and schistosomiasis. Heritable Pulmonary Arterial Hypertension is further classified based on mutations of genes such as BMPR2, ALK-1, ENG, SMAD9, CAV1, KCNK3, and unknown.

Few cases of Pulmonary Arterial Hypertension occur sporadically especially Idiopathic Pulmonary Arterial Hypertension. Mutations of genes such as bone morphogenetic protein receptor type 2 (BMPR2), activin-like kinase type 1 receptor (ALK-1), caveolin 1 (CAV1), endoglin (ENG), potassium channel subfamily K member 3 (KCNK3), leads to the development of Hereditary Pulmonary Arterial Hypertension. Diseases such as scleroderma or lupus, congenital heart defects, liver disease/cirrhosis, and HIV infection increases the chances of developing Pulmonary Arterial Hypertension. Using illicit drugs such as cocaine and methamphetamines also leads to the development of Pulmonary Arterial Hypertension.

Several risk factors can make someone more susceptible to Pulmonary Arterial Hypertension and other heart and lung conditions, such as age, gender, family history, other health conditions, drug use, high altitude, etc. Pulmonary Arterial Hypertension is likely to develop more in young females since the idiopathic form of the disease occurs more often in women of childbearing age than in men. There is an inherited form of Pulmonary Arterial Hypertension, so a family history of the disease may put one at increased risk. Patients with diseases like lupus, scleroderma, cirrhosis of the liver, and HIV infection can also develop it.

The exact cause of Pulmonary Arterial Hypertension is unknown but in Heritable Pulmonary Arterial Hypertension, an autosomal dominant genetic condition, mutations in the BMPR2 gene are the most common cause. Pulmonary Arterial Hypertension leads to disruption in one or more of three key pathways: nitric oxide (NO), prostacyclin (PGI2), thromboxane A2 (TXA2), and endothelin-1 (ET-1) leading to vasoconstriction, increased smooth muscle cell formation, inflammation, and thrombosis. These imbalances contribute to changes in the blood vessels, which further impact the progression of this disease.

Pulmonary Arterial Hypertension Diagnosis

Symptoms usually go unnoticed and may be present for up to 2 or 3 years before a diagnosis is made, often leading to misdiagnosis or a delay in early-stage diagnosis. While the global guidelines for Pulmonary Arterial Hypertension promote cardiac catheterization as the gold standard for diagnosis, transthoracic echocardiography is the most prevalent method of diagnosis. Electrocardiogram (ECG), chest radiography, pulmonary function tests, and blood tests are also done to determine PAH. With improvement in disease understanding, biomarker-based assay and genetic testing are also being done to ascertain PAH. The Six-Minute Walk Test (6MWT) is also a widely used test to determine a patient's activity tolerance and estimated 1-year mortality.

Continued in the report…..

Pulmonary Arterial Hypertension Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Pulmonary Arterial Hypertension, Total Diagnosed Cases of Pulmonary Arterial Hypertension, Age-specific Cases of Pulmonary Arterial Hypertension, Class-specific Cases of Pulmonary Arterial Hypertension, Gender-specific Cases of Pulmonary Arterial Hypertension, and Subtype-specific Cases of Pulmonary Arterial Hypertension scenario of Pulmonary Arterial Hypertension in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Pulmonary Arterial Hypertension Detailed Epidemiology Segmentation

• In 2021, the total prevalent cases of Pulmonary Arterial Hypertension were estimated to be approximately 87,713 cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 0.4% during the study period (2019-2032).
• Among the 7MM, the United States accounted for nearly 58% of the total diagnosed cases of Pulmonary Arterial Hypertension in the 7MM in the year 2021 which are expected to increase further during the study period (2019-2032).
• The age-specific cases of Pulmonary Arterial Hypertension in EU4 and the UK in 2021 were 1,510, 855, 945, 2,251, 3,151, 3,690, 3,872, and 3,419 cases of PAH in the age group <18, 18-25, 26-35, 36-45, 46-55, 56-65, 66-75, and >75, respectively, which are expected to increase during the study period (2019-2032).
• In 2021, in Japan, there were 205 cases of class I, 1,148 cases of class II, 904 cases of class III, and 137 cases of class IV, which is expected to decrease for the study period of 2019-2032.
• The gender distribution of the disease suggests a female predominance in EU4 and the UK. Germany accounted for the highest cases of the affected female population, followed by France in 2021.
• In 2021, in EU4 and the UK, the highest number of subtype-specific cases reported were of idiopathic/heritable PAH, which were approximately 7,720 cases. The cases of drug/toxin induced PAH, connective tissue disease, HIV-related PAH, portopulmonary hypertension, congenital heart disease, and pulmonary veno-occlusive disease were 811, 3,860, 1,327, 1,501, 4,106, and 368, respectively.

Scope of the Report:

• The report covers a descriptive overview of Pulmonary Arterial Hypertension, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of Pulmonary Arterial Hypertension.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, Total Prevalent Cases of Pulmonary Arterial Hypertension, Total Diagnosed Cases of Pulmonary Arterial Hypertension, Age-specific Cases of Pulmonary Arterial Hypertension, Class-specific Cases of Pulmonary Arterial Hypertension, Gender-specific Cases of Pulmonary Arterial Hypertension, and Subtype-specific Cases of Pulmonary Arterial Hypertension.

Report Highlights:

• 11-Year Forecast of Pulmonary Arterial Hypertension
• The 7MM Coverage
• Total Prevalent Cases of Pulmonary Arterial Hypertension
• Total Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension
• Age-specific Cases of Pulmonary Arterial Hypertension
• Class-specific Cases of Pulmonary Arterial Hypertension
• Gender-specific Cases of Pulmonary Arterial Hypertension
• Subtype-specific Cases of Pulmonary Arterial Hypertension

Key Questions Answered

• What are the disease risk and burdens of Pulmonary Arterial Hypertension?
• What is the historical Pulmonary Arterial Hypertension patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Pulmonary Arterial Hypertension at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population with Pulmonary Arterial Hypertension?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Pulmonary Arterial Hypertension during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The Pulmonary Arterial Hypertension report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the 7MM Pulmonary Arterial Hypertension epidemiology forecast.
• The Pulmonary Arterial Hypertension epidemiology report and model were written and developed by Master's and Ph.D. level epidemiologists.
• The Pulmonary Arterial Hypertension epidemiology model developed by DelveInsight is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032